vs
MainStreet Bancshares, Inc.（MNSB）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是MainStreet Bancshares, Inc.的1.1倍（$35.5M vs $32.8M），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -8.8%），MainStreet Bancshares, Inc.自由现金流更多（$10.6M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -0.7%）
MainStreet Bancshares, Inc.是一家总部位于美国的银行控股公司，提供全面的零售及商业银行服务，涵盖存款产品、个人及商业贷款、房屋抵押贷款、财富管理方案，主要服务个人消费者、中小型企业及区域社区客户。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
MNSB vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.1倍
$32.8M
营收增速更快
RXRX
高出690.5%
-8.8%
自由现金流更多
MNSB
多$58.0M
$-47.3M
两年增速更快
RXRX
近两年复合增速
-0.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.8M | $35.5M |
| 净利润 | — | $-108.1M |
| 毛利率 | 55.1% | 59.8% |
| 营业利润率 | 14.9% | -304.8% |
| 净利率 | — | -304.2% |
| 营收同比 | -8.8% | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $0.46 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MNSBRXRX
| Q4 25 | $32.8M | $35.5M | ||
| Q3 25 | $33.6M | $5.2M | ||
| Q2 25 | $35.4M | $19.2M | ||
| Q1 25 | $33.9M | $14.7M | ||
| Q4 24 | $35.9M | $4.5M | ||
| Q3 24 | $34.5M | $26.1M | ||
| Q2 24 | $34.2M | $14.4M | ||
| Q1 24 | $33.3M | $13.8M |
净利润MNSBRXRX
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $4.5M | $-162.3M | ||
| Q2 25 | $4.6M | $-171.9M | ||
| Q1 25 | $2.5M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $265.0K | $-95.8M | ||
| Q2 24 | $2.6M | $-97.5M | ||
| Q1 24 | $3.3M | $-91.4M |
毛利率MNSBRXRX
| Q4 25 | 55.1% | 59.8% | ||
| Q3 25 | 54.3% | -183.8% | ||
| Q2 25 | 56.2% | -4.9% | ||
| Q1 25 | 51.5% | -48.0% | ||
| Q4 24 | 46.9% | -181.4% | ||
| Q3 24 | 47.1% | 53.7% | ||
| Q2 24 | 47.7% | 36.2% | ||
| Q1 24 | 49.4% | 19.1% |
营业利润率MNSBRXRX
| Q4 25 | 14.9% | -304.8% | ||
| Q3 25 | 16.1% | -3327.6% | ||
| Q2 25 | 16.0% | -916.8% | ||
| Q1 25 | 9.2% | -1297.9% | ||
| Q4 24 | -4373.3% | -4042.4% | ||
| Q3 24 | 0.3% | -377.1% | ||
| Q2 24 | 8.4% | -697.4% | ||
| Q1 24 | 12.4% | -698.4% |
净利率MNSBRXRX
| Q4 25 | — | -304.2% | ||
| Q3 25 | 13.4% | -3135.3% | ||
| Q2 25 | 13.0% | -894.2% | ||
| Q1 25 | 7.2% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 0.8% | -367.5% | ||
| Q2 24 | 7.7% | -676.6% | ||
| Q1 24 | 9.9% | -662.4% |
每股收益（稀释后）MNSBRXRX
| Q4 25 | $0.46 | $-0.17 | ||
| Q3 25 | $0.52 | $-0.36 | ||
| Q2 25 | $0.53 | $-0.41 | ||
| Q1 25 | $0.25 | $-0.50 | ||
| Q4 24 | $-2.19 | $-0.56 | ||
| Q3 24 | $-0.04 | $-0.34 | ||
| Q2 24 | $0.27 | $-0.40 | ||
| Q1 24 | $0.36 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $218.6M | $1.1B |
| 总资产 | $2.2B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资MNSBRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务MNSBRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益MNSBRXRX
| Q4 25 | $218.6M | $1.1B | ||
| Q3 25 | $218.4M | $1.0B | ||
| Q2 25 | $213.5M | $919.1M | ||
| Q1 25 | $209.6M | $933.9M | ||
| Q4 24 | $208.0M | $1.0B | ||
| Q3 24 | $226.1M | $524.6M | ||
| Q2 24 | $224.7M | $584.4M | ||
| Q1 24 | $223.1M | $401.2M |
总资产MNSBRXRX
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.1B | $1.4B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.2B | $1.3B | ||
| Q4 24 | $2.2B | $1.4B | ||
| Q3 24 | $2.2B | $726.5M | ||
| Q2 24 | $2.1B | $775.9M | ||
| Q1 24 | $2.1B | $557.8M |
负债/权益比MNSBRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.8M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $10.6M | $-47.3M |
| 自由现金流率自由现金流/营收 | 32.5% | -133.1% |
| 资本支出强度资本支出/营收 | 12.7% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $14.9M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流MNSBRXRX
| Q4 25 | $14.8M | $-46.1M | ||
| Q3 25 | $5.6M | $-117.4M | ||
| Q2 25 | $1.2M | $-76.4M | ||
| Q1 25 | $1.5M | $-132.0M | ||
| Q4 24 | $14.7M | $-115.4M | ||
| Q3 24 | $4.5M | $-59.2M | ||
| Q2 24 | $1.2M | $-82.2M | ||
| Q1 24 | $3.6M | $-102.3M |
自由现金流MNSBRXRX
| Q4 25 | $10.6M | $-47.3M | ||
| Q3 25 | $5.5M | $-117.6M | ||
| Q2 25 | $-2.6M | $-79.6M | ||
| Q1 25 | $1.4M | $-133.8M | ||
| Q4 24 | $13.8M | $-116.7M | ||
| Q3 24 | $4.3M | $-63.8M | ||
| Q2 24 | $1.1M | $-83.4M | ||
| Q1 24 | $3.0M | $-109.0M |
自由现金流率MNSBRXRX
| Q4 25 | 32.5% | -133.1% | ||
| Q3 25 | 16.2% | -2272.5% | ||
| Q2 25 | -7.4% | -413.9% | ||
| Q1 25 | 4.1% | -907.4% | ||
| Q4 24 | 38.5% | -2567.7% | ||
| Q3 24 | 12.5% | -244.6% | ||
| Q2 24 | 3.1% | -578.5% | ||
| Q1 24 | 9.1% | -789.9% |
资本支出强度MNSBRXRX
| Q4 25 | 12.7% | 3.5% | ||
| Q3 25 | 0.4% | 4.7% | ||
| Q2 25 | 10.8% | 16.4% | ||
| Q1 25 | 0.2% | 12.4% | ||
| Q4 24 | 2.5% | 28.6% | ||
| Q3 24 | 0.5% | 17.5% | ||
| Q2 24 | 0.3% | 8.2% | ||
| Q1 24 | 1.8% | 48.2% |
现金转化率MNSBRXRX
| Q4 25 | — | — | ||
| Q3 25 | 1.24× | — | ||
| Q2 25 | 0.26× | — | ||
| Q1 25 | 0.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 16.87× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 1.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
